Safety Study of Allogeneic Mesenchymal Precursor Cell Infusion in Myocardial Infarction

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 106 participants.

Also called NCT01781390

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 106 participants (enrolled count) (from the registry)
Sponsor
Mesoblast, Inc. (from the registry)
Registry
  • NCT NCT01781390
  • EudraCT 2010-020497-41
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Not reported
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01781390. Randomized; quadruple masking; primary purpose treatment. Start 2013-03-11 (actual); primary completion 2021-04-06 (actual). Results posted on 2022-01-18.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety Study of Allogeneic Mesenchymal Precursor Cell Infusion in Myocardial Infarction
Acronym
AMICI
Condition
Acute Myocardial Infarction
Intervention (Other)
Placebo
Intervention (Biological)
Mesenchymal Precursor Cells (MPC) 12.5 M
Intervention (Biological)
Mesenchymal Precursor Cells (MPC) 25 M
Lead sponsor
Mesoblast, Inc. (class: industry)

Record details

Record id
cardio:ct-nct01781390
Content hash
4291d977b65406969a5501204e251775db800eff91858b53ef8a25e684c9eecb